Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Hua

Showing results (51-60 of 101) with videos related to

Pageof 11
Sort By:
American Heart Journal|October 18, 2008
Determining the most appropriate components for a composite clinical trial outcomeM Angelyn Bethel, Rury Holman, Steven M Haffner, et al.
International Journal of Clinical Pharmacology and Therapeutics|October 30, 2001
Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosisJ S Barrett, E Gibiansky, R D Hull, et al.
Cold Spring Harbor Symposia on Quantitative Biology|September 2, 2004
Comparative analysis of human chromosome 22q11.1-q12.3 with syntenic regions in the chimpanzee, baboon, bovine, mouse, pufferfish, and zebrafish genomesB A Roe, C Lau, S Oommen, et al.
European Heart Journal|November 22, 2015
Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trialGiuseppe Mancia, Sverre E Kjeldsen, Dion H Zappe, et al.
European Journal of Heart Failure|June 22, 2013
Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT studyAnastasia Lesogor, Jay N Cohn, Roberto Latini, et al.
Journal of Hypertension|June 15, 2007
Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trialLuis M Ruilope, Alberto Zanchetti, Stevo Julius, et al.
Journal of the American College of Cardiology|July 1, 1986
Effects of esmolol on patients with left ventricular dysfunctionA S Iskandrian, C E Bemis, A H Hakki, et al.
European Heart Journal|January 25, 2018
Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risksMaria H Mehlum, Knut Liestøl, Sverre E Kjeldsen, et al.
The American Journal of Medicine|April 2, 2013
Systolic blood pressure and cardiovascular outcomes during treatment of hypertensionMichael A Weber, George L Bakris, Allen Hester, et al.
Blood Pressure|October 30, 2015
No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trialSverre E Kjeldsen, Eivind Berge, Sripal Bangalore, et al.
Pageof 11

Showing results (51-60 of 101) with videos related to

Sort By:
Pageof 11
American Heart Journal|October 18, 2008
Determining the most appropriate components for a composite clinical trial outcomeM Angelyn Bethel, Rury Holman, Steven M Haffner, et al.
International Journal of Clinical Pharmacology and Therapeutics|October 30, 2001
Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosisJ S Barrett, E Gibiansky, R D Hull, et al.
Cold Spring Harbor Symposia on Quantitative Biology|September 2, 2004
Comparative analysis of human chromosome 22q11.1-q12.3 with syntenic regions in the chimpanzee, baboon, bovine, mouse, pufferfish, and zebrafish genomesB A Roe, C Lau, S Oommen, et al.
European Heart Journal|November 22, 2015
Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trialGiuseppe Mancia, Sverre E Kjeldsen, Dion H Zappe, et al.
European Journal of Heart Failure|June 22, 2013
Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT studyAnastasia Lesogor, Jay N Cohn, Roberto Latini, et al.
Journal of Hypertension|June 15, 2007
Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trialLuis M Ruilope, Alberto Zanchetti, Stevo Julius, et al.
Journal of the American College of Cardiology|July 1, 1986
Effects of esmolol on patients with left ventricular dysfunctionA S Iskandrian, C E Bemis, A H Hakki, et al.
European Heart Journal|January 25, 2018
Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risksMaria H Mehlum, Knut Liestøl, Sverre E Kjeldsen, et al.
The American Journal of Medicine|April 2, 2013
Systolic blood pressure and cardiovascular outcomes during treatment of hypertensionMichael A Weber, George L Bakris, Allen Hester, et al.
Blood Pressure|October 30, 2015
No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trialSverre E Kjeldsen, Eivind Berge, Sripal Bangalore, et al.
Pageof 11